checkAd

Alpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program. ALPHA-1062 administration significantly, acutely reduced the extent of the functional deficit, and improved functional recovery of TBI animals compared to untreated animals suffering a TBI. Notably, in four of five functional measures of recovery, the performance of ALPHA-1062 treated group was statistically indistinguishable from that of the uninjured cohort.

Denis Kay, the Company’s Chief Scientific Officer commented: “These preclinical results, combined with our clinical data demonstrating the safety and tolerability of ALPHA-1062, support its continued development for the treatment of TBI, which we believe has the potential to help millions of Americans who suffer from a TBI each year. We are encouraged by the data thus far and confident in our progress towards developing a safe and effective treatment for this underserved population.”

In a rodent model of TBI, ALPHA-1062 or vehicle (purified water as treatment control) was administered intranasally, with treatment initiated 2 hours after injury and continued twice daily for 35 days. ALPHA-1062 demonstrated acute (functional) protection from injury, and significantly improved:

  1. motor and sensory functional recovery measured by motor skill assessment, sensory/motor skill assessment, and Modified Neurological Severity Score which comprises motor, sensory, balance and reflex assessment.
  2. cognitive functional recovery measured by tests which assess recognition memory, and spatial learning and memory.

The neuropathological assessment of the brains from each experimental group is ongoing and top line results will be released in Q1, 2022.

TBI is a highly prevalent and increasingly common condition, with nearly 3 million diagnosed events occurring in the United States alone in 2019 [DRG Executive Insights - Traumatic Brain Injury, June 2020]. TBI is a major cause of death and disability in the US and there is currently no proven effective pharmacological intervention for patients who sustain an acute closed head injury.

Seite 1 von 3


Nachrichtenquelle: Business Wire (engl.)
06.12.2021, 15:00  |  181   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Alpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative …

Nachrichten des Autors

Titel
Titel
Titel
Titel